Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps "

被引:0
|
作者
Wang, Xu [1 ,2 ,3 ]
Wang, Pu [1 ,2 ,3 ]
Liao, Ying [1 ,2 ,3 ]
Zhao, Xuan [1 ,2 ,3 ]
Hou, Rui [4 ]
Li, Sijin [1 ,2 ,3 ]
Guan, Zhangchun [1 ,2 ,3 ]
Jin, Yuhang [1 ,2 ,3 ]
Ma, Wen [1 ,2 ,3 ]
Liu, Dan [1 ,2 ,3 ]
Zheng, Junnian [2 ,3 ]
Shi, Ming [1 ,2 ,3 ]
机构
[1] Xuzhou Med Univ, Canc Inst, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Ctr Clin Oncol, Affiliated Hosp, 99 Huaihai Rd, Xuzhou 221002, Jiangsu, Peoples R China
[3] Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
[4] Xuzhou Med Univ, Coll Pharm, Xuzhou, Jiangsu, Peoples R China
关键词
Cancer; Drug resistance; Evolutionary Trap; CAR -T therapy; PDPN; LAPATINIB RESISTANCE; CELLS; CANCER; CARCINOMA;
D O I
10.1016/j.phrs.2024.107221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Based on the concept of "Evolutionary Traps", targeting survival essential genes obtained during tumor drug resistance can effectively eliminate resistant cells. While, it still faces limitations. In this study, lapatinib-resistant cells were used to test the concept of "Evolutionary Traps" and no suitable target stand out because of the identified genes without accessible drug. However, a membrane protein PDPN , which is low or non -expressed in normal tissues, is identified as highly expressed in lapatinib-resistant tumor cells. PDPN CAR -T cells were developed and showed high cytotoxicity against lapatinib-resistant tumor cells in vitro and in vivo , suggesting that CAR -T may be a feasible route for overcoming drug resistance of tumor based on "Evolutionary Trap". To test whether this concept is cell line or drug dependent, we analyzed 21 drug -resistant tumor cell expression profiles reveal that JAG1, GPC3, and L1CAM, which are suitable targets for CAR -T treatment, are significantly upregulated in various drug -resistant tumor cells. Our findings shed light on the feasibility of utilizing CAR -T therapy to treat drug -resistant tumors and broaden the concept of the "Evolutionary Trap".
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
    Zhang, Bohan
    Wu, Jiawen
    Jiang, Hua
    Zhou, Min
    CELLS, 2025, 14 (05)
  • [2] CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
    Rodriguez-Garcia, Alba
    Palazon, Asis
    Noguera-Ortega, Estela
    Powell, Daniel J., Jr.
    Guedan, Sonia
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [3] Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells
    Hu, Dong
    Yang, Ruyue
    Wang, Guidan
    Li, Hao
    Fan, Xulong
    Liang, Gaofeng
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2024, 19 : 2773 - 2791
  • [4] Gene Targets of CAR-T Cell Therapy for Glioblastoma
    Wang, Chaoqun
    Li, Yuntao
    Gu, Lijuan
    Chen, Ran
    Zhu, Hua
    Zhang, Xu
    Zhang, Yonggang
    Feng, Shi
    Qiu, Sheng
    Jian, Zhihong
    Xiong, Xiaoxing
    CANCERS, 2023, 15 (08)
  • [5] In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
    Xin, Tianqing
    Cheng, Li
    Zhou, Chuchao
    Zhao, Yimeng
    Hu, Zhenhua
    Wu, Xiaoyan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Overcome tumor relapse in CAR T cell therapy
    Cheng-Dong Huo
    Jie Yang
    Yan-Mei Gu
    Dai-Jun Wang
    Xiao-Xia Zhang
    Yu-Min Li
    Clinical and Translational Oncology, 2022, 24 : 1833 - 1843
  • [7] Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy
    Zhang, Si-Heng
    Peng, Ling-Long
    Chen, Yi-Fei
    Xu, Yan
    Moradi, Vahid
    INFLAMMATION AND REGENERATION, 2024, 44 (01)
  • [8] Overcome tumor relapse in CAR T cell therapy
    Huo, Cheng-Dong
    Yang, Jie
    Gu, Yan-Mei
    Wang, Dai-Jun
    Zhang, Xiao-Xia
    Li, Yu-Min
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (10): : 1833 - 1843
  • [9] Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
    Jo, Yuna
    Ali, Laraib Amir
    Shim, Ju A.
    Ha Lee, Byung
    Hong, Changwan
    CANCERS, 2020, 12 (08) : 1 - 21
  • [10] EXPLORING NOVEL TARGETS FOR CAR-T THERAPY FOR PROSTATE CANCER
    Zhu, J.
    Meyran, D.
    Butler, J.
    Tantalo, D.
    Neeson, M.
    Kershaw, M.
    Trapani, J.
    Darcy, P.
    Neeson, P.
    CYTOTHERAPY, 2019, 21 (05) : E15 - E16